The US Food and Drug Administration (FDA) has granted approval for Medtronic’s OmniaSecure defibrillation lead intended for ...

The Food and Drug Administration (FDA) has cleared the Jewel ® Patch Wearable Cardioverter Defibrillator (Patch-WCD) for adult patients aged 18 years and older who are at risk for sudden cardiac ...

Omniasecure, which was authorized for placement in the heart’s right ventricle, is the world’s smallest defibrillation lead, ...

Medtronic (NYSE: MDT) announced that it received FDA approval for its OmniaSecure defibrillation lead for right ventricle ...

A system hybridizing cardiac contractility modulation and implantable cardioverter defibrillation successfully converted ...

In order to remove obstacles preventing immediate defibrillation, the medical community and the media worked together to highlight the importance of public access defibrillation. Under increasing ...

Medtronic (MDT) received U.S. Food and Drug Administration approval for the OmniaSecure defibrillation lead for placement within the right ...

Kestra Medical Technologies today announced the presentation of new real-world data for its Assure wearable cardioverter ...

Oral semaglutide (Rybelsus) can be tied to a near halving of incident Afib, according to a meta-analysis of 26 randomized ...

Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure defibrillation lead for ...

German medical technology development service provider Corscience has joined AdvaMed, the Advanced Medical Technology ...

Medtronic said its OmniaSecure device can be used to treat potentially life-threatening conditions including ventricular tachyarrhythmias, a heart rhythm disorder where the heart's lower chambers beat ...